F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9845-9853

  Barret, Jean Marc ^a,b   Kruczynski, Anna ^a   Vispé, Stéphane ^a   Annereau, Jean Philippe ^a   Brel, Viviane ^a   Guminski, Yves ^b   Delcros, Jean Guy ^c,e   Lansiaux, Amélie ^d   Guilbaud, Nicolas ^a   Imbert, Thierry ^b   Bailly, Christian ^a  

^a Institut de Recherche Pierre Fahre   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

[2 [3 [4 (3 AMINOPROPYLAMINO)BUTYLAMINO]PROPYLAMINO] 4' NOREPIPODOPHYLLOTOXIN 4 YL]ACETAMIDE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN; ETOPOSIDE; F 14512; POLYAMINE; PUTRESCINE; SPERMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CELL; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG DNA INTERACTION; DRUG UPTAKE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; BINDING, COMPETITIVE; BIOGENIC POLYAMINES; BREAST NEOPLASMS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DRUG DELIVERY SYSTEMS; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA L1210; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS; PODOPHYLLOTOXIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57149094031     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2748     Document Type: Article

References (49)

1. Seiler N, Delcros J, Moulinoux J. Polyamine transport in mammalian cells. An update. Int J Biochem Cell Biol 1996;28:843-61.
2. Scalabrino G, Ferioli M. Polyamines in mammalian tumors. Part II. Adv Cancer Res 1982;36:1-102.
3. Scalabrino G, Ferioli M. Polyamines in mammalian tumors. Part I. Adv Cancer Res 1981;35:151-268.
4. Weiss T, Bernhardt G, Buschauer A, et al. Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade. Int J Colorectal Dis 2002;17:381-7.
5. Rioux-Leclercq N, Delcros J, Bansard J, et al. Immunohistochemical analysis of tumor polyamines discriminates high-risk patients undergoing nephrectomy for renal cell carcinoma. Hum Pathol 2004;35:1279-84.
6. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 2. Structural analogues and derivatives. Curr Drug Targets 2003;4:565-85.
7. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 2003;4:537-64.
8. Wallace H, Niiranen K. Polyamine analogues - an update. Amino Acids 2007;33:261-5.
9. Casero R, Marton L. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007;6:373-90.
10. Bachrach U, Seiler N. Formation of acetylpolyamines and putrescine from spermidine by normal and transformed chick embryo fibroblasts. Cancer Res 1981;41:1205-8.
11. 14C]putrescine and the conversion of putrescine to GABA. FEBS Lett 1981;134:71-4.
12. Cullis P, Green R, Merson-Davies L, Travis N. Probing the mechanism of transport and compartmentalisation of polyamines in mammalian cells. Chem Biol 1999;6:717-29.
13. Igarashi K, Kashiwagi K. Polyamine transport in bacteria and yeast. Biochem J 1999;344(Pt 3):633-42.
14. Hasne M-P, Ullman B. Identification and characterization of a polyamine permease from the protozoan parasite Leishmania major. J Biol Chem 2005;280:15188-94.
15. Soulet D, Covassin L, Kaouass M, et al. Role of endocytosis in the internalization of spermidine-C(2)-BODIPY, a highly fluorescent probe of polyamine transport. Biochem J 2002;367:347-57.
16. Phanstiel O, Kaur N, Delcros J. Structure-activity investigations of polyamine-anthracene conjugates and their uptake via the polyamine transporter. Amino Acids 2007;33:305-13.
17. Holley JL, Mather A, Wheelhouse RT, et al. Targeting of tumor cells and DNA by a chlorambucil-spermidine conjugate. Cancer Res 1992;52:4190-5.
18. Holley J, Mather A, Cullis P, et al. Uptake and cytotoxicity of novel nitroimidazole-polyamine conjugates in Ehrlich ascites tumour cells. Biochem Pharmacol 1992;43:763-9.
19. Eiseman JL, Rogers FA, Guo Y, et al. Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer. Cancer Res 1998;58:4864-70.
20. Delcros J, Tomasi S, Carrington S, et al. Effect of spermine conjugation on the cytotoxicity and cellular transport of acridine. J Med Chem 2002;45:5098-111.
21. Suzuki I, Shigenaga A, Nemoto H, Shibuya M. Synthesis and DNA damaging ability of enediynepolyamine conjugates. Tetrahedron Lett 2004;2004:1955-9.
22. Cunha AS, Lima ELS, Pinto AC, et al. Synthesis of novel naphtoquinone-spermidine conjugates and their effects on DNA-topoisomerases Iand II-a. J Braz Chem Soc 2006;17:439-42.
23. Dallavalle S, Giannini G, Alloatti D, et al. Synthesis and cytotoxic activity of polyamine analogues of camptothecin. J Med Chem 2006;49:5177-86.
24. Pang J, Long Y, Chen W, Jiang Z. Amplification of DNA-binding affinities of protoberberine alkaloids by appended polyamines. Bioorg Med Chem Lett 2007;17:1018-21.
25. Verschoyle R, Carthew P, Holley J, et al. The comparative toxicity of chlorambucil and chlorambucil-spermidine conjugate to BALB/c mice. Cancer Lett 1994;85:217-22.
26. Mandel J, Flintoff W. Isolation of mutant mammalian cells altered in polyamine transport. J Cell Physiol 1978;97:335-43.
27. Wang C, Delcros J, Biggerstaff J, Phanstiel O. Synthesis and biological evaluation of N1-(anthracen-9-ylmethyl)triamines as molecular recognition elements for the polyamine transporter. J Med Chem 2003;46:2663-71.
28. Bailly C. DNA relaxation and cleavage assays to study topoisomerase Iinhibito rs. Methods Enzymol 2001;340:610-23.
29. Perrin D, van Hille B, Barret JM, et al. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases Iand II with an original mechanism of action. Biochem Pharmacol 2000;59:807-19.
30. Olive P, Banath J. Induction and rejoining of radiation-induced DNA single-strand breaks: "tail moment" as a function of position in the cell cycle. Mutat Res 1993;294:275-83.
31. Olive PL, Banath JP, Durand RE. Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells. J Natl Cancer Inst 1990;82:779-83.
32. Barret JM, Etievant C, Baudouin C, et al. F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells. Anticancer Res 2002;22:187-92.
33. Kruczynski A, Etievant C, Perrin D, Imbert T, Colpaert F, Hill BT. Preclinical antitumor activity of F11782, a novel dual catalytic inhibitor of topoisomerases. Br J Cancer 2000;83:1516-24.
34. Teicher BA. In vivo tumor response end points. In: Teicher BA, editor. Tumor models in cancer research. Totowa (NJ): Humana Press; 2002. p. 593-616.
35. Plowman J, Dykes D, Hollingshead M, et al. Human tumor xenograph models in NCIdrug development. In: Teicher BA, editor. Anticancer drug development guide. Totowa (NJ): Humana Press; 1997. p. 101-25.
36. Corbett T, Valeriote F, Demchik L, et al. Preclinical anticancer activity of cryptophycin-8. J Exp Ther Oncol 1996;1:95-108.
37. Wilstermann A, Bender R, Godfrey M, et al. Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. Biochemistry 2007;46:8217-25.
38. Bender R, Jablonksy M, Shadid M, et al. Substituents on etoposide that interact with human topoisomerase IIα in the binary enzyme-drug complex: contributions to etoposide binding and activity. Biochemistry 2008;47:4501-9.
39. Gardner R, Delcros J, Konate F, et al. N1-substituent effects in the selective delivery of polyamine conjugates into cells containing active polyamine transporters. J Med Chem 2004;47:6055-69.
40. Cullis P, Green R, Merson-Davies L, Travis N. Chemical highlights of polyamine transport. Biochem Soc Trans 1998;26:595-601.
41. Jeggo P, Kemp L. X-ray-sensitive mutants of Chinese hamster ovary cell line. Isolation and cross-sensitivity to other DNA-damaging agents. Mutat Res 1983;112:313-27.
42. Chen F, Peterson S, Story M, Chen D. Disruption of DNA-PK in Ku80 mutant xrs-6 and the implications in DNA double-strand break repair. Mutat Res 1996;362:9-19.
43. Swaffar D, Ireland C, Barrows L. A rapid mechanism-based screen to detect potential anti-cancer agents. Anticancer Drugs 1994;5:15-23.
44. Verhaegh G, Jongmans W, Morolli B, et al. A novel type of X-ray-sensitive Chinese hamster cell mutant with radioresistant DNA synthesis and hampered DNA double-strand break repair. Mutat Res 1995;337:119-29.
45. Gahl W, Pitot H. Reversal by aminoguanidine of the inhibition of proliferation of human fibroblasts by spermidine and spermine. Chem Biol Interact 1978;22:91-8.
46. Kramer D, Miller J, Bergeron R, et al. Regulation of polyamine transport by polyamines and polyamine analogs. J Cell Physiol 1993;155:399-407.
47. Lindemose S, Nielsen PE, Mollegaard NE. Polyamines preferentially interact with bent adenine tracts in double-stranded DNA. Nucleic Acids Res 2005;33:1790-803.
48. Wang L, Price H, Juusola J, et al. Influence of polyamine architecture on the transport and topoisomerase II inhibitory properties of polyamine DNA-intercalator conjugates. J Med Chem 2001;44:3682-91.
49. Cullis P, Merson-Davies L, Weaver R. Conjugation of a polyamine to the bifunctional alkylating agent chlorambucil does not alter the preferred cross-linking site in duplex DNA. J Am Chem Soc 1995;117:8033-4.